Zilovertamab vedotin
- Generic Name
- Zilovertamab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2376463-48-6
- Unique Ingredient Identifier
- IZY9ZSI6FI
- Background
Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1046
- Registration Number
- NCT06717347
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06395103
- Locations
- 🇨🇳
National Taiwan University Hospital ( Site 1983), Taipei, Taiwan
🇺🇸Children's Mercy Hospital ( Site 1024), Kansas City, Missouri, United States
🇺🇸Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota, United States
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT05562830
- Locations
- 🇨🇱
FALP-UIDO ( Site 1151), Santiago, Region M. De Santiago, Chile
🇮🇱Rambam Health Care Campus-Oncology ( Site 1501), Haifa, Israel
🇺🇸Cleveland Clinic-Taussig Cancer Center ( Site 1036), Cleveland, Ohio, United States
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 223
- Registration Number
- NCT05458297
- Locations
- 🇺🇸
Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona, United States
🇺🇸University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin, United States
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05406401
- Locations
- 🇰🇷
Seoul National University Hospital ( Site 0201), Seoul, Korea, Republic of
🇰🇷Samsung Medical Center ( Site 0200), Seoul, Korea, Republic of
🇨🇦BC Cancer Victoria-Clinical Trials Unit ( Site 0105), Victoria, British Columbia, Canada
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 290
- Registration Number
- NCT05139017
- Locations
- 🇦🇺
Grampians Health ( Site 1802), Ballarat, Victoria, Australia
🇨🇳The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan, China
🇨🇷CIMCA ( Site 2501), San Jose, Costa Rica
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
- Conditions
- Triple-negative Breast CancerNSCLCNon-squamous Non-small-cell Lung CancerEstrogen-receptor-positive Breast CancerGastric CancerProgesterone-receptor-positive Breast CancerEstrogen-receptor-negative Breast CancerER-negative Breast CancerProgesterone-receptor Negative Breast CancerPR-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 102
- Registration Number
- NCT04504916
- Locations
- 🇺🇸
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005), Hollywood, Florida, United States
🇺🇸John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002), Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center ( Site 0007), New York, New York, United States
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-01-12
- Target Recruit Count
- 91
- Registration Number
- NCT03833180
- Locations
- 🇺🇸
City of Hope ( Site 0010), Duarte, California, United States
🇺🇸University of California - San Diego ( Site 0003), La Jolla, California, United States
🇺🇸UCLA Hematology & Oncology ( Site 0007), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.